TRILEPTAL ORAL SUSPENSION 60 MG
OXCARBAZEPINE : 60 MG · DIN 02244673 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is TRILEPTAL ORAL SUSPENSION?
TRILEPTAL ORAL SUSPENSION 60 MG contains OXCARBAZEPINE : 60 MG. It is listed in the Health Canada Drug Product Database under DIN 02244673, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 05-Sep-2002. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRILEPTAL ORAL SUSPENSION used for?
Monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children ages 6-16.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02244673 |
|---|---|
| Brand name | TRILEPTAL ORAL SUSPENSION |
| Generic / active ingredient | OXCARBAZEPINE : 60 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 60 MG |
| Dosage form | SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AF02 OXCARBAZEPINE |
| AHFS class | 84:80.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 05-Sep-2002 |
How is it administered?
Adults: Start 600 mg/day BID. Increase by max 600 mg/day weekly. Target 1200-2400 mg/day. Pediatrics (6-16): Start 8-10 mg/kg/day BID. Target dose based on weight. Administer with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 mentioned in TOC but text cuts off). Standard practice refers to room temperature.
How is it supplied?
Tablets: PVC/PE/PVDC blister packs of 50. Oral Suspension: 250 mL amber glass bottles with 10 mL dosing syringe and adaptor.
Contraindications
Known hypersensitivity to oxcarbazepine or eslicarbazepine acetate or to any of the components of TRILEPTAL.
Warnings and precautions
Serious dermatologic reactions (SJS/TEN), especially in HLA-B*1502 positive patients. Hematologic effects (agranulocytosis, aplastic anemia). Clinically significant hyponatremia.
What can be used instead?
Other Canadian products sharing ATC code N03AF02 OXCARBAZEPINE. 9 of 22 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OXCARBAZEPINE | 150 MG | TABLET | APOTEX INC | MARKETED | DIN 02284294 |
| APO-OXCARBAZEPINE | 300 MG | TABLET | APOTEX INC | MARKETED | DIN 02284308 |
| APO-OXCARBAZEPINE | 600 MG | TABLET | APOTEX INC | MARKETED | DIN 02284316 |
| JAMP OXCARBAZEPINE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02560593 |
| JAMP OXCARBAZEPINE | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02560607 |
| JAMP OXCARBAZEPINE | 600 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02560615 |
| TRILEPTAL 300 MG | 300 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02242068 |
| TRILEPTAL 600 MG | 600 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02242069 |
| JAMP-OXCARBAZEPINE | 150 MG | TABLET | JAMP PHARMA CORPORATION | CANCELLED POST MARKET | DIN 02440717 |
| JAMP-OXCARBAZEPINE | 300 MG | TABLET | JAMP PHARMA CORPORATION | CANCELLED POST MARKET | DIN 02440725 |
Who else supplies OXCARBAZEPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OXCARBAZEPINE appears in 50 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.